NasdaqGS:RVMDBiotechs
Revolution Medicines (RVMD) Wins FDA Approval For Metastatic Pancreatic Cancer Drug
Revolution Medicines (NasdaqGS: RVMD) received FDA approval for RASONQUE (daraxonrasib), the first broad RAS targeted oral therapy for adults with metastatic pancreatic adenocarcinoma.
The once daily treatment is the company’s first approved RAS(ON) inhibitor, following a pivotal Phase 3 trial that showed statistically significant and clinically meaningful survival benefits.
RASONQUE is now available by prescription in the U.S., addressing a major unmet need in metastatic pancreatic cancer...